Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Atyr Pharma Inc (NASDAQ: ATYR) was $0.99 for the day, down -5.70% from the previous closing price of $1.05. In other words, the price has decreased by -$5.70 from its previous closing price. On the day, 9.36 million shares were traded. ATYR stock price reached its highest trading level at $1.05 during the session, while it also had its lowest trading level at $0.98.
Ratios:
Our analysis of ATYR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.63 and its Current Ratio is at 5.63. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
On September 15, 2025, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $1. Leerink Partners Downgraded its Outperform to Market Perform on September 15, 2025, while the target price for the stock was maintained at $1.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 17 ’25 when Gross Jane A bought 3,750 shares for $4.00 per share. The transaction valued at 15,000 led to the insider holds 9,750 shares of the business.
Broadfoot Jill Marie sold 1,254 shares of ATYR for $4,740 on Feb 04 ’25. The Chief Financial Officer now owns 31,763 shares after completing the transaction at $3.78 per share. On Feb 04 ’25, another insider, DENYES NANCY, who serves as the General Counsel of the company, sold 899 shares for $3.78 each. As a result, the insider received 3,398 and left with 26,555 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATYR now has a Market Capitalization of 97016568 and an Enterprise Value of 35028964.
Stock Price History:
The Beta on a monthly basis for ATYR is 0.80, which has changed by -0.42441863 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, ATYR has reached a high of $7.29, while it has fallen to a 52-week low of $0.94. The 50-Day Moving Average of the stock is -79.19%, while the 200-Day Moving Average is calculated to be -75.60%.
Shares Statistics:
ATYR traded an average of 9.27M shares per day over the past three months and 33275700 shares per day over the past ten days. A total of 97.99M shares are outstanding, with a floating share count of 95.98M. Insiders hold about 2.05% of the company’s shares, while institutions hold 67.61% stake in the company. Shares short for ATYR as of 1756425600 were 29405110 with a Short Ratio of 3.17, compared to 1753920000 on 25598382. Therefore, it implies a Short% of Shares Outstanding of 29405110 and a Short% of Float of 35.889998.
Earnings Estimates
The dynamic stock of Atyr Pharma Inc (ATYR) is currently being evaluated by a team of 11.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.06 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.59 and -$0.85 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.59, with 11.0 analysts recommending between -$0.22 and -$1.23.
